DNAprint Genomics (DNAG)

[cosmiclifeform]

Ann... The PR I referenced on the IPO was from Biofrontera's announcement of their DNAP deal.

This was Biofrontera's own release in Europe. The link I provided was from a news service as I had trouble accessing Biofrontera's website for the PR.

Your PR was from the DNAPrint Genomics announcement about the Biofrontera partnership and has a lot of good stuff in it as well.

Dr. Tony's statement in the PR about the value of the partnership for DNAP shareholders:

I believe this is the [drug company] deal all DNAPrint shareholders have been waiting for...

The full quote conveys the excitement:

“I believe the value of population genomics lies in the sale of highly targeted drug/test combinations. The new DNAPrint/Biofrontera represents to me an example of the paradigm that most 21st century drug development firms should adhere to – using population genomics to develop and obtain approval for “smart” drugs targeting specific patient subpopulations with highly predictable efficacy and minimal side effects,” said Tony Frudakis, DNAPrint’s Founder and CSO. “As a scientist, I am delighted at the prospect of working with Biofrontera scientists. I believe this is the deal all DNAPrint shareholders have been waiting for – and we hope that it will put DNAPrint on the map.”

Both PR's state that the new partnership will provide investors with exciting possibilities (along with of course the normal disclaimers).

In DNAP's PR - Biofrontera's statement about "shareholder value":

"Including DNAPrint's technology in our clinical studies for the selection of patients will reduce the cost of our studies and should allow more rapid development. We consider the ability to predict the individual patient's response to our drugs an extremely valuable addition to our effort in serving the patients' needs. Capital from this investment will also fund the development of Biofrontera’s other clinical and preclinical projects and will us to move towards our goal of enhanced shareholder value.”

In Biofrontera's PR - Biofrontera's statement about a possible IPO is much more direct:

"We consider the ability to predict the individual patient's response to our drugs an extremely valuable addition to our effort in serving the patients' needs. Rapid success in drug development will move Biofrontera towards its goal of an initial public offering.”

I like the excitement Dr. Luebbert and Tony conveys about the possibilities and potential of DNAP/Biofrontera working together and Biofrontera's clear game plan towards an IPO based on their novel drug compounds "tailored to the individual"...

Lots of good stuff. Thanks!

God Bless and take care,

Robert